Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival As A First-Line Maintenance Therapy For Advanced Non-Small Cell Lung Cancer

Genentech, Inc., (NYSE: DNA) and OSI Pharmaceuticals, Inc.

Related Posts

  1. Significant Free Knowledgebase Pertaining To Where To Purchase Oticon Bte Digital Hearing Aids
  2. December Issue Of Cell Features NIDA-Funded Study That Focuses On The Generation Of Stem Cell Lines In Rats

Tags: , ,

Comments are closed.